1 陈竺. 中华人民共和国卫生部全国第三次死因回顾

抽样调查报告[M]. 北京:中国协和医科大学出版社,

2008:10-17.

2 王文志. 中国脑血管病防治研究现状和发展方向[J]. 中

国现代神经疾病杂志, 2011, 11:134-137.

3 中华医学会神经病学分会脑血管病学组急性缺血性脑

卒中诊治指南撰写组. 中国急性缺血性脑卒中诊治指

南2010[J]. 中华神经科杂志, 2010, 43:146-153.

4 Kaplan ZS, Jackson SP, Hematology AM, et al. The

role of platelets in atherothrombosis[J]. Hematology

Am Soc Hematol Educ Program, 2011, 1:51-61.

5 Haeke W, Kaste M, Bluhmki E, et al. Thrombolysis

with alteplase 3 to 4.5 hours after acute ischemic

stroke[J]. N Engl J Med, 2008, 359:1317-1329.

6 中华医学会神经病学分会脑血管病学组缺血性脑卒

中二级预防指南撰写组. 中国缺血性脑卒中和短暂性

脑缺血发作二级预防指南2010[J]. 中华神经科杂志,

2010, 43:154-160.

7 Fitzgerald R, Pirmohamed M. Aspirin resistance:effect

of clinical, biochemical and genetic factors[J].

Pharmacol Ther, 2011, 130:213-225.

8 Buonamici P, Marcucci R, Migliorini A, et al. Impact

of platelet reactivity after clopidogrel administration

on drug-eluting stent thrombosis[J]. J Am Coll Cardiol,

2007, 49:2312-2317.

9 Go r e l i ck PB, Fa r o o q MU. Ad va n c e s i n ou r

understanding of "resistance" to antiplatelet agents

for prevention of ischemic stroke[J]. Stroke Res Treat,

2013, 2013:727842.

10 Vane JR. Inhibition of prostaglandin synthesis as a

mechanism of aspirin-like Drugs[J]. Nat New Biol,

197l, 231:232-235.

11 Weber AA, Przytulski B, Schanz A, et al. Towards

a def inition of aspirin resistance:a typological

approach[J]. Platelets, 2002, 13:37-40.

12 Patrono C, Coller B, Dalen JE. The relationship among

dose, effectiveness, and side effects[J]. Chest, 2001,

119:39S-63S.

13 Simon T, Verstuyf t C, Mar y-Krause M, et al.

Genetic determinants of response to clopidogral and

cardiovascular events[J]. N Engl J Med, 2009, 360:363-

375.

14 Sharma V, Kaul S, Al-Hazzani A, et al. Association of

C3435T multi drug resistance gene-1 polymorphism

with aspirin resistance in ischemic stroke and its

subtypes[J]. J Neurol Sci, 2012, 315:72-76.

15 Russel FG, Koenderink JB, Masereeuw R. Multidrug

resistance protein 4 (MRP4/ABCC4):a versatile efflux

transporter for drugs and signalling molecules[J].

Trends Pharmacol Sci, 2008, 29:200-207.

16 Schuetz JD, Connelly MC, Sun D, et al. MRP4:A

previously unidentif ied factor in resistance to

nucleoside-based antiviral drugs[J]. Nat Med, 1999,

5:1048-1051.

17 Mattiello T, Guerriero R, Lotti LV, et al. Aspirin

extrusion from human platelets through multidrug

resistance protein-4-mediated transport:evidence of a

reduced drug action in patients after coronary artery

bypass grafting[J]. J Am Coll Cardiol, 2011, 58:752-761.

18 Ansari M, Sauty G, Labuda M, et al. Polymorphisms

in multidrug resistance-associated protein gene

4 is associated with outcome in childhood acute

lymphoblastic leukemia[J]. Blood, 2009, 114:1383-1386.

19 Fitzgerald DJ, Maree A. Aspirin and clopidogrel

resistance[J]. Hematology Am Soc Hematol Educ

Program, 2007:114-120.

20 Wang LH, Hajibeigi A, Xu XM, et al. Characterization

of the promoter of human prostaglandin H synthase-1

gene[J].Biochem Biophys Res Commun, 1993,

190:406-411.

21 Maree AO, Curtin RJ, Chubb A, et al. Cyclooxygenase-1

haplotype modulates platelet response to aspirin[J]. J

Thromb Haemost, 2005, 3:2340-2345.

22 Ag nd e z JA, Ma r t ne z C, P r e z -Sa l a D, e t a l .

Pharmacogenomics in aspirin intolerance[J]. Curr Drug

Metab, 2009, 10:998-1008.

23 Li Q, Chen BL, Ozdemir V, et al. Frequency of genetic

polymorphisms of COX-1, GPIIIa and P2Y1 in a

Chinese population and association with attenuated

response to aspirin[J]. Pharmacogenomics, 2007, 8:577-

586.

24 Shi J, Misso N L, Duffy D L, et al. Cyclooxygenase-1

gene polymorphisms in patients with different asthma

phenotypes and atopy[J]. Eur Respir J, 2005, 26:249-

256.

25 李晓利, 曹剑, 范利, 等. 中国老年心脑血管疾病患者阿

司匹林抵抗与环氧化酶-1单体型关联分析[J]. 中国应

用生理学杂志, 2012, 28:225-229.

26 Caughey GE, Cleland LG, Penglis PS, et al. Roles of

cyclooxygenase (COX)-1 and COX-2 in prostanoid

production by human endothelial cells:selective upregulation

of prostacyclin synthesis by COX-2[J]. J

Immunol, 2001, 167:2831-2838.

27 Papaf ili A, Hill MR, Brull DJ, et al. Common

promoter variant in cyclooxygenase-2 represses

gene expression:evidence of role in acute-phase

inflammatory response[J]. Arterioscler Thromb Vasc

Biol, 2002, 22:1631-1636.

28 Sharma V, Kaul S, Al-Hazzani A, et al. Association of

COX-2 rs20417 with aspirin resistance[J]. J Thromb

Thrombolysis, 2013, 35:95-99.

29 王毅盟, 倪培华, 杨蓉, 等. 环氧化酶-2启动子区基因单

核苷酸多态性与老年人阿司匹林抵抗的关系[J]. 上海

交通大学学报(医学版), 2012, 32:301-306.

30 Unoki M, Furuta S, Onouchi Y et al. Association

studies of 33 single nucleotide polymorphisms (SNPs)

in 29 candidate genes for bronchial asthma:positive

association a T924C polymorphismin the thromboxane

A2 receptor gene[J]. Hum Genet, 2000, 106:440-446.

31 Fujiwara T, Ikeda M, Esumi K, et al. Exploratory

aspirin resistance trial in healthy Japanese volunteers

(J-ART) using platelet aggregation as a measure of

thrombogenicity[J]. Pharmacogenomics, 2007, 7:395-

403.

32 Gao F, Wang ZX, Men JL, et al. Effect of polymorphism

and type II diabetes on aspirin resistance in patients

with unstable coronary artery disease[J]. Chin Med J

(Engl), 2011, 124:1731-1734.

33 Herrera-Galeano JE, Becker DM, Wilson AF, et al. A

novel variant in the platelet endothelial aggregation

receptor-1 gene is associated with increased platelet

aggregability[J]. Arterioscler Thromb Vasc Biol, 2008,

28:1484-1490.

34 Kunicki TJ, Nugent DJ. The genetics of normal platelet

reactivity[J]. Blood, 2010, 116:2627-2634.

35 Lewis JP, Ryan K, O'Connell JR. Genetic variation

in PEAR1 is associated with platelet aggregation and

cardiovascular outcomes[J]. Circ Cardiovasc Genet,

2013, 6:184-192.

36 吴涛, 姜瑞民, 苏颖. 血小板膜糖蛋白研究进展[J]. 北

京医学, 2011, 33:701-703.

37 Pamukcu B, Oflaz H, Nisanci Y. The role of platelet

glycoprotein IIIa polymorphism in the high prevalence

of in vit ro aspir in resistance in patients with

intracoronary stent restenosis[J]. Am Heart J, 2005,

149:675-680.

38 Goodman T, Ferro A, Sharma P. Pharmacogenetics

of aspirin resistance:a comprehensive systematic

review[J]. Br J Clin Pharmacol, 2008, 66:222-232.

39 茅新蕾, 颜雪琴, 韩丽雅, 等. 阿司匹林抵抗与GPⅢa基

因多态性的相关性研究[J]. 现代实用医学, 2011, 23:18-

21.

40 Yonal I, Hindilerden F, Hancer VS, et al. The impact

of platelet membrane glycoprotein Ib alpha and Ia/

IIa polymorphisms on the risk of thrombosis in the

antiphospholipid syndrome[J]. Thromb Res, 2012,

129:486-491.

41 苏冠华, 王朝晖, 丁艳萍, 等. 血小板膜糖蛋白I a 807C/

T多态性与阿司匹林抵抗的关系[J]. 中国血液流变学

杂志, 2007, 17:43-45.

42 Ma r t e a u F, Le Po u l E , Commu n i D, e t a l .

Pharmacological characterization of the human P2Y13

receptor[J]. Mol Pharmacol, 2003, 64:104-112.

43 Savi P, Zachayus JL, Delesque-Touchard N, et al.

The active metabolite of Clopidogrel disrupts P2Y12

receptor oligomers and partitions them out of lipid

rafts[J]. Proc Natl Acad Sci USA, 2006, 103:11069-

11074.

44 Feher G, Feher A, Pusch G, et al. The genetics of

antiplatelet drug resistance[J]. Clin Genet, 2009, 75:1-

18.

45 Topçuoglu MA, Arsava EM, Ay H. Antiplatelet

resistance in stroke[J]. Expert Rev Neurother, 2011,

11:251-263.

46 Ma TK, Lam YY, Tan VP, et al. Impact of genetic and

acquired alteration in cytochrome P450 system on

pharmacologic and clinical response to clopidogrel[J].

Pharmacol Ther, 2010, 125:249-259.

47 Hol lopet e r G, Jant zen HM, Vincent D, et al.

Identification of the platelet ADP receptor targeted by

antithrombotic drugs[J]. Nature, 2001, 409:202-207.

48 Rai M, Seip RL, Gupta A , et al. CYP2C19 genotypeguided

antiplatelet therapy in a patient with clopidogrel

resistance[J]. Conn Med, 2012, 76:267-272.

49 Fontana P, Dupont A, Gandrille S, et al. Adenosine

diphosphate-induced platelet aggregation is associated

with P2Y12 gene sequence variations in healthy

subjects[J]. Circulation, 2003, 108:989-995.

50 Fontana P, Gaussem P, Aiach M, et al. P2Y12 H2

haplotype is associated with peripheral arterial

disease:a case-control study[J]. Circulation, 2003,

108:2971-3973.

51 von Beckerath N, von Beckerath O, Koch W, et al.

P2Y12 gene H2 haplotype is not associated with

increased adenosine diphosphate-induced platelet

aggregation after initiation of clopidogrel therapy with

a high loading dose[J]. Blood Coagul Fibrinolysis,

2005, 16:199-204.

52 Gurbel PA, Bliden KP. Durability of platelet inhibition

by clopidogrel[J]. Am J Cardiol, 2003, 91:1123-1125.

53 Price MJ, Berger PB, Teirstein PS, et al. Standardvs

high-dose clopidogrel based on platelet function

testing after percutaneous coronary intervention:the

GRAVITAS randomized t r ial[J]. JAMA, 2011,

305:1097-1105.

54 Hashimoto H, Toide K, Kitamura R, et al. Gene

structure of CYP3A4, an adult-specific form of

cytochrome P450 in human livers, and its transcriptional

control[J]. Eur J Biochem, 1993, 218:585-595.

55 Angiollo DJ, Fernandez-Ortiz A, Bernardo E, et

al. Contribution of gene sequence variations of the

hepatic cyto-chrome P450 3A4 enzyme to variability in

individual responsiveness to clopidogrel[J]. Arterioscler

Thromb Vasc Bio, 2006, 26:1895-1900.

56 韩雅玲, 麦晓燕, 李毅, 等. 细胞色素P450 3A4 894C>T

位点基因多态性与氯吡格雷抵抗的关系[J]. 解放军医

学杂志, 2008, 33:939-942.

57 Fontana P, Hulot JS, Moerloose P, et al. Influence

of CYP2C19 and CYP3A4 gene polymorphism on

clopidogrel responsiveness in healthy subjects[J]. J

Thromb Haemost, 2007, 5:2153-2155.

58 Kit zmi l le r J P, Groen DK, Phelps MA, e t a l.

Pharmacogenomic testing:Relevance in medical

practice:Why drugs work in some patients but not in

others[J]. Cleve Clin J Med, 2011, 78:243-257.

59 Coutts RT, Urichuk LJ. Polymorphic cytochromes P450

and drugs used in psychiatry[J]. Cell Mol Neurobiol,

1999, 19:325-354.

60 Rai M, Seip RL, Gupta A, et al. CYP2C19 genotypeguided

antiplatelet therapy in a patient with clopidogrel

resistance[J]. Conn Med, 2012, 76:267-272.

61 Varenhorst C, James S, Erlinge D, et al. Genetic

variation of CYP2C19 affects both pharmacokinetic

and pharmacodynamic responses to clopidogrel but

not prasugrel in aspirin-treated patients with coronary

artery disease[J]. Eur Heart J, 2009, 30:1744-1752.

62 Suh JW, Koo BK, Zhang SY, et al. Increased risk of

atherothrombotic events associated with cytochrome

P450 3A5 p olymor ph i sm i n pa t ie nt s t a k i ng

clopidogrel[J]. CMAJ, 2006, 174:1715-1722.

63 Jia DM, Chen ZB, Zhang MJ, et al. CYP2C19

polymorphisms and antiplatelet effects of clopidogrel

in acute ischemic stroke in China[J]. Stroke, 2013,

44:1717-1719.